Key takeaways
- Novo Nordisk's investigational drug CagriSema demonstrated an average 25% weight loss in female clinical trial participants.
What happened
Novo Nordisk announced that a post-hoc analysis of Phase III clinical trial data for its investigational dual-agonist combination drug, CagriSema, showed that female participants achieved an average weight loss of 25%. This substantial reduction in body weight remained consistent across all stages of menopause, including pre-, peri-, and postmenopausal stages. The drug combines the active ingredient in Wegovy (semaglutide) with cagrilintide, a novel amylin analogue.
Why it matters
For US buyers navigating the clinical weight-loss landscape, this data establishes a highly competitive efficacy benchmark. CagriSema is positioned to challenge existing therapies like Eli Lilly's Zepbound (tirzepatide) and represents a significant leap forward from current single-agonist treatments.
As many patients turn to online providers and cash-pay clinical options due to insurance denials, the development of a dual-agonist compound that delivers a 25% average weight reduction offers a highly potent future alternative. Furthermore, the consistent performance across different menopausal stages is particularly meaningful for middle-aged women, who frequently report hormonal hurdles to weight loss and are major consumers of medical weight-loss services.
What the data says
According to trial data published by MedPage Today, the clinical performance of the semaglutide-cagrilintide combination highlights a shifting paradigm in metabolic medicine:
- 25% average weight loss: Female trial participants lost a quarter of their body weight on average during the study period.
- Hormonal consistency: The weight-reduction efficacy did not fluctuate based on hormonal status, showing virtually identical success rates for premenopausal, perimenopausal, and postmenopausal women.
- Multi-hormone benefits: Separate meta-analysis data from Phase III trials of multi-hormone receptor modulators indicated that greater weight reduction is strongly associated with larger drops in blood pressure, providing critical cardiovascular support alongside weight loss.
This safety and efficacy profile addresses a major demographic in the US cash-pay market, as CDC data from 2025 indicated that nearly half of American women aged 40 to 60 reported menopausal symptoms.
How it compares
CagriSema's 25% weight loss benchmark surpasses the clinical trial results of today's leading single-agonist and dual-agonist therapies:
- Wegovy (semaglutide): In its landmark clinical trials, Wegovy drove an average weight loss of roughly 15%. CagriSema adds cagrilintide to this base, resulting in a 10% increase in average weight loss.
- Zepbound (tirzepatide): Eli Lilly's tirzepatide, a dual GIP/GLP-1 receptor agonist, has demonstrated average weight loss of up to 20.9% in trials. The new CagriSema data indicates Novo Nordisk's combination may surpass this benchmark.
- Retatrutide: Eli Lilly's investigational triple-agonist, retatrutide, has shown exceptional promise, but CagriSema's 25% figure cements it as a top-tier contender in the next-generation pipeline.
For consumers evaluating options via CompareRx telehealth providers, these pipeline updates outline what to expect as the market shifts from standard weekly GLP-1s to more potent multi-hormone therapies.
How this fits the bigger picture
The weight-loss market is undergoing a rapid evolution as pharmaceutical manufacturers rush to develop multi-receptor compounds. This post-hoc analysis builds on previous clinical milestones that are reshaping how telehealth buyers approach long-term obesity care.
Our previous coverage has tracked this intensifying race. In Novo CagriSema beats tirzepatide in REIMAGINE 5 trial, we highlighted how Novo Nordisk's combination drug successfully outperformed Eli Lilly’s current flagship product in head-to-head testing. Additionally, Eli Lilly is advancing its own next-generation pipeline, as we discussed in Lilly’s retatrutide drives 18.8% weight loss in diabetes trial, proving that multi-hormone agonists are the clear future of clinical weight management.
By establishing that CagriSema retains its 25% efficacy across all stages of menopause, Novo Nordisk has answered a critical clinical question regarding patient demographics. As brand-name shortages continue to impact US buyers, knowing the long-term clinical potential of these upcoming dual-agonists helps cash-paying patients decide whether to start treatment with current options or wait for next-generation approvals. To understand how these upcoming therapies compare to what is currently available online, buyers can review our guide on compounded vs. brand-name semaglutide to make informed choices.
What happens next
CagriSema remains in Phase III clinical development, with further trial readouts expected to clarify its side-effect profile, tolerability, and exact timeline for FDA submission. Novo Nordisk will continue to analyze data from its broader clinical trial program to prepare for regulatory filings.
In the meantime, telehealth providers continue to expand access to currently approved therapies. Patients interested in starting their weight-loss journey can use the CompareRx questionnaire to explore available options, view current GLP-1 side effects, and find the cheapest telehealth GLP-1 platforms currently serving US consumers.
Disclaimer: CompareRx does not provide medical advice. Always consult a licensed healthcare provider before starting any medical weight-loss program or medication.